The relationship of carbohydrate intake with fecal short chain fatty acids in persons with IBS and healthy controls

IBS 患者和健康对照者碳水化合物摄入量与粪便短链脂肪酸的关系

• 批准号: 10273130
• 负责人: Angelita Gaoiran Utleg
• 金额: $ 2.33万
• 依托单位: UNIVERSITY OF WASHINGTON
• 依托单位国家: 美国
• 财政年份: 2020
• 资助国家: 美国
• 起止时间: 2020-11-16 至 2022-05-15
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10273130
• 关键词: Abdominal Pain; Acetates; Address; Affect; American; Animals; Bacteria; Behavior Therapy; Biochemical; Biochemistry; Biological Assay; Biological Markers; Brain; Butyrates; Carbohydrates; Chronic; Clinical; Clinical Research; Colon; Communication; Complex; Constipation; Control Groups; Data; Development; Diagnosis; Diarrhea; Diet; Diet Records; Dietary Fats; Dietary Fiber; Dietary Intervention; Dietary intake; Disaccharides; Disease; Educational workshop; Electrical Resistance; Enrollment; Ensure; Environment; Epithelial Cells; Feces; Fermentation; Fiber; Food; Frequencies; Funding; Gastrointestinal Diseases; Gastrointestinal tract structure; Generations; Goals; Grant; Gut Mucosa; Health; Health Expenditures; Human; Impairment; Individual; Intake; Intestinal permeability; Intestines; Irritable Bowel Syndrome; Link; Literature; Maintenance; Measures; Mentorship; Metabolic; Modeling; Molecular; Monosaccharides; Morphology; Mucositis; National Research Service Awards; Nurses; Oligosaccharides; Opitz trigonocephaly syndrome; Pain; Patients; Pattern; Persons; Pharmacology; Phenotype; Physiological; Population; Prevalence; Production; Propionates; Recurrence; Reporting; Research; Research Project Grants; Research Proposals; Resources; Ribosomal DNA; Risk Factors; Role; Rome; Sampling; Scientist; Severities; Subgroup; Symptoms; Therapeutic; Tight Junctions; Training; Validation; Volatile Fatty Acids; base; bile acid metabolism; branched chain fatty acid; cohort; design; diagnostic criteria; diaries; dietary constituent; dietary restriction; dysbiosis; epidemiology study; evidence base; experience; fatty acid metabolism; gastrointestinal; gastrointestinal symptom; gut dysbiosis; gut health; gut inflammation; gut microbiome; gut microbiota; gut-brain axis; improved; in silico; insight; interest; metabolic profile; metabolome; metabolomics; microbial; microbiome; microbiome alteration; novel; polyol; reduce symptoms; repaired; skills; stool sample; study characteristics; symptom management; trait; uptake

PROJECT SUMMARY/ABSTRACT. The PA-19-196 Ruth L. Kirschstein National Research Service Award to Promote Diversity in Health-Related Research will provide the candidate the continued training she needs to become an independent nurse scientist. Irritable bowel syndrome (IBS) is a prevalent gastrointestinal (GI) disorder that affects >35 million Americans and health care expenditures are estimated to be >20 billion dollars. Persons with IBS experience recurrent abdominal pain accompanied with diarrhea and/or constipation. Risk factors for IBS include low-grade mucosal inflammation, altered intestinal permeability, as well as gut dysbiosis (microbial imbalance). Recently, the gut microbiome and its metabolites were identified as important factors contributing to altered brain-gut- microbiome communication. Of relevance to this application is the role of diet and its relationship to the gut microbiota and IBS symptoms. Approximately 64%-89% of the IBS population report that food is a trigger for their IBS symptoms. Current research literature supports the hypothesis that diet modifies gut microbiome and altered gut microbiota (dysbiosis) may be responsible for the initiation and maintenance of IBS symptoms. Pharmacologic and behavioral therapies are effective for only about 50% of persons with IBS. Carbohydrate restriction diets such as low Fermented Oligosaccharides Disaccharides Monosaccharides and Polyols dietary intervention has shown efficacy in some IBS patients, but have also been shown to decrease gut microbial diversity and reduce the production of short chain fatty acids (SCFAs). The primary focus for this proposal is to characterize the fecal SCFA metabolome of healthy individuals and persons with IBS in relation to diet. SCFAs are used by colon epithelial cells for energy, thus ensuring adequate resources for repair and barrier integrity. The purpose of this descriptive study is to explore the links among dietary fiber (DF) intake, 16SrDNA data, fecal SCFAs, and GI symptoms (e.g., abdominal pain, diarrhea and constipation) and to add further insights about IBS pathobiology and symptom management. The long-term goal is to provide preliminary data for the development of evidence-based personalized dietary interventions for IBS symptoms. This project will use 3-day food diary, 28-day IBS symptom diary, and 16S rDNA data, and stool samples from individuals who participated in a study by the sponsor's team (Microbiome & Abdominal Pain Study, NR014479). The novel component of this research will be the focus on SCFAs using targeted metabolomics approach in fecal samples and their relationship to daily symptoms. Stool samples from IBS (n=30) and healthy controls (n=30) will be randomly chosen and assayed at Northwest Metabolomics Research Center and assayed at Northwest Metabolomics Research Center. Funding from this NRSA grant will provide the support to complete Ms. Utleg's dissertation research project, enroll in relevant courses and participate in attending microbiome seminars and workshops, expert mentorship, and dissemination of findings.

项目总结/摘要。 PA-19-196 Ruth L. Kirschstein国家研究服务奖，以促进健康相关的多样性 研究将为候选人提供继续培训，她需要成为一名独立的护士 科学家肠易激综合征（IBS）是一种流行的胃肠道（GI）疾病，影响超过3500万人 美国人和医疗保健支出估计为> 200亿美元。有IBS经历的人 反复腹痛伴腹泻和/或便秘。IBS的风险因素包括低级别 粘膜炎症、肠通透性改变以及肠道生态失调（微生物失衡）。最近， 肠道微生物组及其代谢物被确定为导致脑-肠- 微生物组通信。与此相关的应用是饮食的作用及其与肠道的关系 微生物群和IBS症状。大约64%-89%的IBS人群报告说，食物是诱发IBS的诱因。 IBS症状目前的研究文献支持饮食改变肠道微生物组的假设， 肠道微生物群的改变（生态失调）可能是IBS发生和维持的原因 症状药物和行为疗法仅对约50%的IBS患者有效。 碳水化合物限制饮食，如低发酵寡糖、二糖、单糖和 多元醇饮食干预在一些IBS患者中显示出有效性，但也显示出减少肠道 减少微生物多样性，减少短链脂肪酸（SCFA）的产生。这方面的主要焦点是 建议是表征健康个体和IBS患者的粪便SCFA代谢组， 饮食. SCFA被结肠上皮细胞用作能量，从而确保足够的资源用于修复和屏障。 完整本研究的目的是探讨膳食纤维（DF）摄入量、16 SrDNA 数据、粪便SCFA和GI症状（例如，腹痛，腹泻和便秘），并添加进一步的见解 肠易激综合征的病理学和症状管理长期目标是提供初步数据， 开发针对IBS症状的基于证据的个性化饮食干预。该项目将使用3天 食物日记，28天IBS症状日记，16 S rDNA数据，以及来自参与者的粪便样本 在一项由赞助商团队进行的研究中（微生物组和腹痛研究，NR 014479）。新的组成部分， 这项研究将集中在SCFAs使用靶向代谢组学方法在粪便样本， 与日常症状的关系。来自IBS（n=30）和健康对照（n=30）的粪便样品将被 随机选择并在西北代谢组学研究中心进行测定，并在西北 代谢组学研究中心从这个NRSA赠款的资金将提供支持，以完成乌特莱格女士的 论文研究项目，报名参加相关课程，参加微生物组研讨会， 讲习班、专家指导和传播调查结果。